Singapore markets closed
Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,032.03 +13.64 (+0.27%) Dow
37,998.15 +94.86 (+0.25%) Nasdaq
15,688.86 +83.38 (+0.53%) Bitcoin USD
58,356.30 +711.62 (+1.23%) CMC Crypto 200
1,265.68 -5.06 (-0.40%)
REGN May 2024 840.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:40PM EDT. Market open.
| Previous close | 4.1000 |
| Open | 4.6000 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 840.00 |
| Expiry date | 2024-05-17 |
| Day's range | 4.1000 - 4.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 44 |
GuruFocus.comRegeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ...
First Quarter Results Show Revenue Decline but Strong Dupixent and Libtayo Sales Growth
Simply Wall St.Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...
GlobeNewswireRegeneron Reports First Quarter 2024 Financial and Operating Results
First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP dil
© 2024 Yahoo. All rights reserved.